Related Experiment Video
Updated: Mar 21, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
25.2K
Loss of Dnmt3b accelerates MLL-AF9 leukemia progression
1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Leukemia
|May 3, 2016
Summary
DNA methyltransferase 3B (Dnmt3b) deletion accelerated MLL-AF9 acute myeloid leukemia (AML) progression by increasing stemness and cell cycle activity. Dnmt3b acts as a tumor suppressor in AML.
Area of Science:
- Epigenetics
- Hematopoiesis
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer with poor outcomes.
- Aberrant DNA methylation is a key factor in AML development and progression.
- The roles of DNA methyltransferases, particularly Dnmt3b, in AML remain unclear.
Purpose of the Study:
- To investigate the function of Dnmt3b in MLL-AF9 induced AML.
- To determine if Dnmt3b acts as a tumor suppressor or oncogene in AML.
Main Methods:
- Mice with Dnmt3b deletion were used to study MLL-AF9 leukemia progression.
- Gene profiling analysis was performed to assess gene expression changes.
- Synergistic effects with Dnmt3a deficiency were examined.
Main Results:
- Deletion of Dnmt3b accelerated MLL-AF9 leukemia progression.
- Loss of Dnmt3b increased cancer stemness and cell cycle progression.
- Gene profiling showed oncogene upregulation and differentiation gene downregulation.
- Dnmt3b deficiency synergized with Dnmt3a deficiency in leukemia development.
Conclusions:
- Dnmt3b plays a significant tumor suppressive role in MLL-AF9 AML.
- These findings offer new insights into DNA methylation's role in leukemia.
- Targeting Dnmt3b could be a potential therapeutic strategy for AML.
